533 results about "Liver adenocarcinoma" patented technology

The present invention relates to pharmaceutical compositions and dietary supplement comprising yeast cells that can produce a healthful benefit in a subject inflicted with liver cancer. The biological compositions can be used to retard the growth of liver cancer cells and / or prolonging the time of survival of the subject. The invention also relates to methods for manufacturing the biological compositions.

The invention discloses a meso-porous silicon nano-drug carrier with both reduction responsiveness and targeting ability and a preparation method thereof. Firstly, meso-porous silicon nano-particles are prepared with a sol-gel method, and are developed into a nanometer reservoir of drug molecules; then a disulfide bond is introduced into the surface of the meso-porous silicon nanometer reservoir with a simple chemical modification method and is used as a cohesive tie; secondarily, a biocompatible natural extracellular matrix-collagen molecule is creatively fixed to the surface of the meso-porous silicon nanometer reservoir and is developed into a nanometer encapsulator of the meso-porous silicon nanometer reservoir; and finally a lactobionic acid molecule is modified to the surface of a meso-porous silicon / collagen nanometer compounding system and is used as a specificity receptor of a liver cancer cell membrane surface receptor (ASGP-R) so as to construct a meso-porous silicon / collagen-lactobionic acid multifunctional compound type nano-drug carrier system with both cell specificity targeting ability and reducing substance / enzyme responsiveness.

An anticancer kaurane-type diterpenoid for suppressing esophagus cancer and liver cancer cells is extracted from the stem of soursop through drying in air, pulverizing, extracting in alcohol concentrating, extracting in chloroform, chromatography, eluting, chromatography and eluting. Its advantages are high effect, low toxic by-effect, broad spectrum and high activity.

The invention discloses a class of anti-tumor compounds containing a triazole heterocyclic structure and an application thereof, belonging to the technical field of medicinal chemistry. The compounds containing the triazole heterocyclic structure introduce quintuple 1,2,3-triazole ring in the form of side chains through the amino condensation, bromination, nitrine substitution, link reaction and other reactions on the basis of naphthalimide parent structure, select tetrazolium salt reduction to test 7721 hepatocellular in the experiment of inhibiting proliferation of tumor cells, and also select sulfonyl rhodamine B protein staining method to test MCF-7 breast cancer cells. The experiment results show that the anti-tumor compounds have wide anti-tumor activity and good inhibition effect on the normal growth of tumor cells derived from different tissues of liver cancer, breast cancer and the like.

The invention relates to the medicine technical field, in particular to saponin compounds of Siraitic acid IIB and Siraitic acid IIC which are extracted and separated from fructus momordicae roots, a method for preparing the same and application thereof in an anti-tumor medicine. The molecular formulas of the two compounds are C40H60O14 and C41H62O15 respectively. By various modern spectral analysis, particularly the application of advanced two-dimensional nuclear magnetic resonance spectrum to comprehensive analysis, the chemical structures of the two compounds are determined. In vitro anti-tumor tests show that the compound Siraitic acid IIB can obviously inhibit lung cancer cells A-549 and liver cancer cells Hep-G2, and the compound Siraitic acid IIC can also obviously inhibit liver cancer cells Hep-G2. The invention provides lead compound for research on a new anti-tumor medicine, and has essential values in comprehensively developing and utilizing fructus momordicae resources.

The present invention relates to the use of cytotoxicity based on the effector function of anti-CDH3 antibodies. Specifically, the present invention provides methods and pharmaceutical compositions that comprise an anti-CDH3 antibody as an active ingredient for damaging CDH3-expressing cells using antibody effector function. Since CDH3 is strongly expressed in pancreatic, lung, colon, prostate, breast, gastric or liver cancer cells, the present invention is useful in pancreatic, lung, colon, prostate, breast, gastric or liver cancer therapies.

The invention relates to a CRISPR / Cas12a gene editing system and application thereof. The invention comprehensively utilizes biochemical, molecular biology, cell biology and other methods to screen and identify novel LiCas12a protein with endonuclease activity from a plurality of different bacteria. Based on LiCas12a, a CRISPR / LiCas12a gene editing system with high editing efficiency and high specificity is established in eukaryotic cells and prokaryotic cells separately, and genetic manipulation such as knockout, insertion and point mutation of genes is achieved; a molecular mechanism that the mutation of a TERT gene promoter promotes the cell proliferation of bladder cancer and liver cancer is disclosed. The genetic editing system based on CRISPR-LiCas12a provides a more accurate and efficient gene editing method for research fields such as disease pathogenesis and metabolic engineering transformation.

The invention relates to a rat liver cancer model with different liver matrix hardness backgrounds and a preparation method of the rat liver cancer model. The method for preparing the rat liver cancer model with different liver matrix backgrounds is characterized by specifically comprising the following steps of: after grouping the rats, injecting pure carbon tetrachloride to an abdominal region in a hypodermic manner; injecting a carbon tetrachloride-olive oil solution to the abdominal region in the hypodermic manner; detecting through a texture analyzer to form the rat model with different liver matrix hardness; taking liver cancer cells which are in-vitro cultured and grown well and injecting the liver cancer cells to the rat to form hypodermic liver cancer cells; in-situ planting the formed liver cancer tumor source to the rat model with different liver matrix hardness to obtain the rat liver cancer model with different liver matrix hardness backgrounds. The rat liver cancer model with different liver matrix hardness backgrounds can be used for well displaying liver cancer malignant pathological characteristics under the liver matrix hardness interference, simulating and reproducing pathological characteristics of clinical liver matrix hardening background liver cancer and solving the problems that an ideal experiment system, an animal model and the like are lacked in reaching the development of the liver cancer due to the liver matrix hardness changes.

The present invention relates to anti-CDH3 antibodies, which can be labeled with a radioisotope. Moreover, the present invention provides methods and pharmaceutical compositions that comprise an anti-CDH3 antibody as an active ingredient. Since CDH3 is strongly expressed in pancreatic, lung, colon, prostate, breast, gastric or liver cancer cells, the present invention is useful in pancreatic, lung, colon, prostate, breast, gastric or liver cancer therapies.

The invention discloses a method to produce ADI strain by screening and the application of the method, pertaining to the field of bioengineering technology. The invention particularly relates to a rapid method to screen ADI strain and produce Pseudomonas plecoglossicida (CGMCC No.2039) of ADI, as well as a method to produce ADI by using the microorganism. Under an aerobic condition and an environment maintained at pH6.5-8.0, enzyme activity can achieve 1.6U / mL fermentation broth after 20-24h fermentation culture. ADI produced with such microorganism has very strong inhabitation agaisnt liver cancer cell strain (HepG2). ADI genes can be obtained from the chromosome DNA of such microorganism, and the gene order can be achieved.

A lactone monomer compound used for preparing the medicines to prevent and treat cancer, especially the liver cancer is prepared from soursop seeds through drying, breaking, reflux extracting in alcohol, concentrating, suspending the extract in water, extracting sequentially by petroether, water saturated ethyl acetate and water saturated n-butanol, purifying, and recrystallizing.

The invention belongs to the technical field of chemical and pharmaceutical industry and particularly relates to the application of mogrol H9 for preparing antitumor drugs. The invention provides the application of mogrol H9 for preparing antitumor medicaments. The tumor cell can be liver cancer cell, leukaemia cell, cervical carcinoma cell, lung adenocarcinoma cell, stomach cancer cell, breast cancer cell or pancreatic cancer cell. The compound H9 is a natural product, has less toxic and adverse effects, high bioavailability and stable property, and is significant in clinical use. The small molecule compound is developed as a new antitumor drug or antitumor effective component, has an obvious antitumor effect, is green and environment-friendly, and provides a new approach to treatment and healing of tumors.

The invention relates an anticancer active part of fructus terminaliae billericae, and a preparation method of the anticancer active part. The invention comprises extraction of the part containing active components, study of a process for enriching by adopting macroporous absorption resin, identification of the active components in the active part, and use of the active part in in-vivo or in-vitroinhibition of liver cancer HepG2, lung cancer A549, lung adenocarcinoma NCI-H1703, gastric cancer BGC823, osteosarcoma cell MG-63, colorectal cancer HCT116, breast cancer MCF-7, neuroblastoma cells shsy5y, kidney cancer ACHN, normal liver cells L02, human breast ductal carcinoma cells ZR75-1, human colorectal adenocarcinoma cells Colo-205, human breast ductal carcinoma cells BT-474, human breastcancer cells T-47D, human cervical cancer cell line HeLa, liver cancer cells H22, and the like. The enrichment method applying the macroporous absorption resin to the anti-cancer active part of the fructus terminaliae billericae is simple in process, safe, non-toxic and low in production cost, and can be used for industrial production, thus having a great economic benefit and higher generalizationperformance.

The invention provides the application of carbon nanotube-chitosan-phycocyanin complex in the preparation of antitumor drugs. The carbon nanotube-chitosan-phycocyanin complex is composed of multi-walled carbon nanotubes, Chitosan and spirulina phycocyanin are formed by non-covalent combination. The complex has good growth inhibitory effect on breast cancer MCF-7 cells and liver cancer HepG2 cells, especially under the irradiation of near-infrared light and visible light. The inhibitory effect was further strengthened, and all showed the characteristics of killing tumor cells. As an anti-tumor biomedical material, the carbon nanotube-chitosan-phycocyanin composite provided by the invention has broad prospects in photodynamic therapy and photothermal therapy of tumor cells.

The invention provides a bispecific antibody resisting a CD16A antigen and an MUC1 antigen. The bispecific antibody comprises a first functional domain capable of specifically recognizing the CD16A antigen of immunologic effector cells, a second functional domain capable of specifically recognizing the MUC1 antigen of liver cancer cells and a linker linking the two functional domains. According to the technical scheme, the bispecific antibody can combine tumor-associated antigen and target molecules of immune cells, can recognize the MUC1 antigen of the liver cancer cells and induce ADCC (antibody-dependent cell-mediated cytotoxicity) and recognize the CD16A antigen of the immunologic effector cells, improves the killing capacity of NK (natural killer) cells on tumor cells, effectively guides the immunologic effector cells to perform specific killing on the tumor cells and has a stable structure and a longer half-life period.

The invention discloses a class of compounds with antitumor activity. The structural formula is as follows: In the formula, R is one or two substituents of ethynyl, chlorine, fluorine, trifluoromethyl and 3-fluorobenzyloxy; X is O or NH; Y is CH2 or CO (carbonyl); Z is H or methoxy; n=5 or 6. The salicylic amide compounds in the structural formula are synthesized from 5-nitrosalicylic acid or 4-methoxysalicylic acid and aniline derivatives through amidation, reduction, and reaction with monoethyl pimelic acid chloride. . The compound has a novel structure and the synthesis method is easy to realize. The anti-tumor activity test showed that it has inhibitory effect on the growth of human liver cancer cells (HepG-2), human colon cancer (SW 480) and human prostate cancer cells (PC3), and the activity of most compounds is stronger than that of gefitinib. The use of preparing anti-tumor drug preparations.

The invention discloses an N-alkyl-1,2,3,4,5,6-hexahydro-1,1,5,5-tetramethyl-7H-2,4 alpha-methanonaphthalene-7-amine compound as well as a synthetic method and an application thereof. Longifolene serving as a heavy oil main component is relatively rich terpenoid in numerous natural extracts. The synthetic method comprises the following steps: obtaining isolongifolene through longifolene isomerization, obtaining isolongifolenone through allylic oxidation of the isolongifolene, carrying out dehydration condensation on the isolongifolenone and primary amine so as to obtain imine and obtaining the chiral N-alkyl-1,2,3,4,5,6-hexahydro-1,1,5,5-tetramethyl-7H-2,4 alpha-methanonaphthalene-7-amine compound after reduction. The compound has vey good inhibition activity on candida albicans, aspergillus niger, candida tropicalis, escherichia coli, staphylococcus aureus, pseudomonas fluorescens, bacillus subtilis and the like, a part of compound has good cancer cell proliferation inhibition activity on human breast cancer cells MCF-7, human lung adenocarcinoma cells A549, hepatoma cells HepG2 and SMMC-7721, and the N-alkyl-1,2,3,4,5,6-hexahydro-1,1,5,5-tetramethyl-7H-2,4 alpha-methanonaphthalene-7-amine compound is a potential antibacterial and bactericidal and anti-tumor compound.

The invention relates to dibenzo iodonium salts represented by the following structural formula (I), and discloses a preparation method and an application thereof. In in-vitro experiments, the iodonium salts substantially inhibit the growths of cells of human-sourced pancreatic cancer, stomach cancer, colon cancer and other malignant tumors, and provide substantially killing effects against cells of ovarian cancer, lung cancer, liver cancer, leukemia, glioma, bone marrow cancer and other malignant tumors. In animal experiments, with the salts, the growths of human pancreatic cancer and colon cancer xenografts in nude mice can be substantially inhibited. The compounds can be used in developing novel antitumor medicines. (I) is shown below.

Disclosed are a method for detecting liver cancer capable of detecting liver cancer with high specificity and a diagnostic therefor, as well as a novel therapeutic drug for cancer having an excellent anticancer effect. The method for detecting liver cancer cells in a sample utilizes as an index the expression of dlk gene. The expression of dlk gene may be measured by immunoassay using an anti-dlk antibody or by measuring mRNA of dlk gene. The therapeutic drug for cancer comprises as an effective ingredient an antibody which undergoes antigen-antibody reaction with Dlk expressing on surfaces of cancer cells and which exerts anticancer action against the cancer cells.

The invention discloses a novel preparation technology of targeting antitumor fusion protein (lipid peroxidation). The novel preparation method comprises the steps of building a fusion expression protein which takes the glutathione S-transferase A (TrxA)-His-tag (His6-Tag)-SUMO protease recognition substrate as a protein soluble expression auxiliary fragment and takes LHRH (luteinizing hormone releasing hormone)-PEA (phenylethylamine) trans-cell penetrating peptides-ONC (LPO for short) as a target segment, connecting the two proteins with each other by a correct read frame and carrier positive sequence and converting to enter into expression bacteria, finally building fusion protein which is connected with six expression substances in series, crudely extracting, carrying out metal chelating medium purification in the presence of imidazole, and carrying out SUMO protease digestion. Compared with the LPO prepared by a conventional method, the LPO prepared by the novel preparation technology disclosed by the invention can obviously improve the inhibiting effect on the tumor cell lines such as colon cancer HT-29 cells, ovarian cancer OVCAR3 cells, cervical adenocarcinoma HeLa cells and liver cancer HepG-2 cells.

The invention discloses a liver-cancer-targeted doxorubicin-supporting silica-gold composite material, and a preparation method and application thereof. The composite material comprises silica-gold nanometer core-shell particles, a targeting adhesion peptide and doxorubicin; doxorubicin is subjected to chemical modification for forming A SH-PEG-Dox prodrug, and the prodrug is linked to silica-gold nanometer core-shell particles via Au-S bonds; and the targeting adhesion peptide is linked to the silica-gold nanometer core-shell particles via Au-S bonds. The material is good in biological compatibility, has specific optical properties and good targeting property, the material can enable the supported medicine to be transferred to liver cancer cells and rapidly releases the medicine, and the material has the cooperative treatment effects of chemotherapy and thermotherapy.

The invention belongs to the technical field of new drug synthesis, in particular to a class of 4-amino-6-(3-(3-bromophenyl)phenyl)-5-cyano-7-(β-L-xylofuranose)pyrrolo [2,3-d]pyrimidine, its similar derivatives, and drugs for preparing anti-human liver cancer cells, human lung cancer cells, human breast cancer cells, human cervical cancer cells, and human gastric cancer cells. The compounds of the present invention are directed against 4-amino-6-(3-(3-bromophenyl)phenyl)-5-cyano-7-(β-L-xylofuranose)pyrrolo[2,3 -d] The C6 position of pyrimidine is modified and synthesized by chemical methods. Experiments have shown that this type of compound can significantly inhibit the proliferation of various cancer cells, effectively induce apoptosis of cancer cells, including highly metastatic cancer cells, and can be used as drugs and drug components for treating cancer.

The invention discloses a compound lithocarolsA-F, a preparation method and application thereof in preparation of antitumor drugs. The compound lithocarolsA-F is isolated from a fermentation culture of marine fungi Phomopsis lithocarpus FS508. Experiments prove that the IC50 values of the compound lithocarolsA-F on liver cancer cells HepG-2, breast cancer cells MCF-7, glioma cells SF-268 and non-small cell lung cancer cells A549 are 10.5-87.7 muM, showing that the compound lithocarolsA-F has relatively significant antitumor activity and can be used for preparing antitumor drugs.

The invention relates to a hydrophilic chlorin photo-sensitive and sono-sensitive agent with long wavelength and a preparation method and an application thereof, and belongs to the field of chemical medicine. The compound is represented as the following formula described in the description. The compound of hydrophilic chlorin photo-sensitive and sono-sensitive agent with long wavelength has inhibition effects in different degrees on human liver cancer cell Hep G2 in anticancer activity evaluation in vitro. The ratio of photoactivity to dark activity and the ratio of sono-activity to dark activity are much higher than that of hemoporphyrinmonomethyl ether as a positive contrast. The hydrophilic chlorin photo-sensitive and sono-sensitive agent with long wavelength has advantages of low toxicity, high efficiency, treatment wavelength moving towards long wave region and the like. The compound in the invention can be used as an excellent photosensitizer and an excellent sonosensitizer for photodynamic and sonodynamic therapy of tumors.

The invention provides a tree peony root bark, as well as a preparation method and application thereof. The preparation method comprises the following steps: extracting a tree peony root bark medicinal material with organic alcohol aqueous solution, concentrating and drying to obtain the tree peony root bark extract. The tree peony root bark extract can inhibit glucose-regulated protein GRP78, and is used for resisting virus. In-vitro experiments prove that: the tree peony root bark extract has remarkable effect in resisting hepatitis B virus secretion, has small toxicity to normal cells and liver cancer cells, and has excellent application prospect.

The invention discloses application of H22 liver cancer cell autophagosome DRibbles to the preparation of a liver cancer therapeutic vaccine. Liver cancer is one of the most common malignant tumors in China and can be effectively prevented by developing a liver cancer vaccine; and years of research results prove that tumor cell autophagosome is one of effective vectors for tumor antigen cross-presentation. The application comprises a core technology for extracting the autophagosome DRibbles from human liver cancer cells and proves that the autophagosome can effectively induce anti-tumor immune response of organisms and has a good biotherapy prospect.

The invention relates to ursolic acid derivatives with anticancer activity and a preparation method thereof. In the method, a carbonoxyl group at the C-28 position of ursolic acid is connected with natural alpha-amino acid through ethanediamine in a mode of forming an amido bond to synthesize a series of ursolic acid derivatives with anticancer activity. In-vitro pharmacological experiments indicate that the ursolic acid derivatives chemically modified by amino acid have obvious in-vitro inhibition effect on human liver cancer HepG2 cells, human colon cancer HT-29 cells, human gastric cancer AGS and BGC-823cells, and human prostatic cancer PC-3 cells.

The invention belongs to the biological medicine field, in particular relating to the use of a high efficiency small interfering RNA for preparing a tumor migration inhibition drug. The high efficiency small interfering RNA can silence the expression of survivin, change the adhesive force of breast cancer, gastric cancer and liver cancer cells against IV collagen, and inhibit the migrating ability of the breast cancer, gastric cancer and liver cancer cells at two-and three-dimensional levels. The small interfering RNA can also prepare the drug for inhibiting the tumor migration.

The invention relates to a preparation method of hydronopyl triethyl ammonium iodide, and an application of the prepared hydronopyl triethyl ammonium iodide in preparation of an inhibitor for treating tumor. The compound has obvious inhibition effect for tumor cells, and the preparation method of hydronopyl triethyl ammonium iodide is characterized in that hydronopyl chlorine is reacted to sodium iodide to prepare hydronopyl iodine, and the hydronopyl iodine is reacted to triethylamine to obtain hydronopyl triethyl ammonium iodide. The prepared hydronopyl triethyl ammonium iodide has median inhibitory concentration 50 (IC50 ) value of human lung cancer H460 cells, human breast cancer MCF7 cells, human liver cancer SMMC7721 cells, human stomach cancer MK-45 cells as 8.3mum g / ml, 13.25mum g / ml, 2.28mum g / ml and 1.27mum g / ml, which are most basically less than 10 mum g / ml, and partially achieves the requirements of SFDA antitumor drug pharmacodynamics guidance principle, and expresses good antineoplastic activity.

The invention relates to a yellow mushroom standardized component manufacturing method. The method comprises the following steps: (1) drying and crushing yellow mushrooms, then performing water extraction, centrifugally collecting mushroom residues, extracting the mushroom residues with acetone, centrifugally collecting filtrate, and performing reduced pressure concentration on the filtrate to form paste, namely an acetone extract; (2) dissolving the acetone extract in an n-hexane-ethyl acetate mixed solution, then filtering to obtain a sample solution containing the acetone extract, and separating the sample solution containing the acetone extract on a preparation chromatogram to obtain 14 standardized component samples, namely Fr1, Fr2,..., Fr13 and Fr14; and (3) performing anti-liver cancer cell model screening in vitro on the 14 standardized component samples by an iCelligence real-time label-free cell analyzer, thus determining that the 7th, the 8th, the 9th, the 10th, the 11th, the 13th and the 14th standardized component have human liver cancer cell adherence and proliferation inhibition activity in vitro. The yellow mushroom standardized component manufacturing method provided by the invention has the advantages of simple process and easiness in implementation. Simultaneously, the obtained active components can be applied to treatment of liver cancer.